Evotec SE (NASDAQ:EVO) Sees Significant Growth in Short Interest

Evotec SE (NASDAQ:EVOGet Free Report) was the recipient of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 158,300 shares, an increase of 10.2% from the May 15th total of 143,700 shares. Based on an average trading volume of 136,400 shares, the short-interest ratio is presently 1.2 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Evotec

A number of hedge funds have recently modified their holdings of the stock. Mubadala Investment Co PJSC purchased a new position in Evotec in the 4th quarter valued at approximately $53,931,000. Optiver Holding B.V. grew its stake in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after buying an additional 69,936 shares in the last quarter. Cetera Advisors LLC purchased a new position in Evotec in the 1st quarter valued at approximately $188,000. Finally, Quadrant Capital Group LLC purchased a new position in Evotec in the 4th quarter valued at approximately $25,000. Institutional investors own 5.81% of the company’s stock.

Evotec Price Performance

Shares of NASDAQ:EVO traded down $0.01 during mid-day trading on Tuesday, reaching $4.07. The company had a trading volume of 139,768 shares, compared to its average volume of 116,849. The company has a current ratio of 1.86, a quick ratio of 1.79 and a debt-to-equity ratio of 0.43. The company’s 50-day moving average price is $5.44 and its 200-day moving average price is $7.46. Evotec has a one year low of $3.94 and a one year high of $13.49.

Analyst Upgrades and Downgrades

EVO has been the subject of several research reports. Deutsche Bank Aktiengesellschaft upgraded Evotec from a “hold” rating to a “buy” rating in a research note on Friday, April 12th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Evotec in a research note on Thursday, May 23rd.

View Our Latest Stock Analysis on EVO

About Evotec

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.

Read More

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.